Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.
Vogelmeier CF, Naya IP, Maltais F, Bjermer L, Kerwin EM, Tombs L, Jones PW, Compton C, Lipson DA, Boucot IH. Vogelmeier CF, et al. Among authors: boucot ih. Int J Chron Obstruct Pulmon Dis. 2021 May 3;16:1215-1226. doi: 10.2147/COPD.S295835. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33976543 Free PMC article. Clinical Trial.
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF. Maltais F, et al. Among authors: boucot ih. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9. Respir Res. 2019. PMID: 31666084 Free PMC article. Clinical Trial.
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L. Kerwin EM, et al. Among authors: boucot ih. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926949. doi: 10.1177/1753466620926949. Ther Adv Respir Dis. 2020. PMID: 32462979 Free PMC article. Clinical Trial.
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F. Vogelmeier CF, et al. Among authors: boucot ih. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620968500. doi: 10.1177/1753466620968500. Ther Adv Respir Dis. 2020. PMID: 33167780 Free PMC article. Clinical Trial.
49 results